Efficacy of tolvaptan on nephrotic patients with diuretic-resistant edema: a pilot study

Ryo Matsuura (rimatsuura- tky@umin.ac.jp)
University of Tokyo Hospital
https://orcid.org/0000-0003-4936-4852

Takayasu Ohtake
Shonan Kamakura General Hospital

Yasuhiro Mochida
Shonan Kamakura General Hospital

Kunihiro Ishioka
Shonan Kamakura General Hospital

Hidekazu Moriya
Shonan Kamakura General Hospital

Sumi Hidaka
Shonan Kamakura General Hospital

Teruhiko Imamura
Toyama University

Koichiro Kinugawa
Toyama University

Shuzo Kobayashi
Shonan Kamakura General Hospital

Research article

Keywords: nephrotic syndrome, vasopressin receptor type 2 antagonist, aquaporin 2, diuretics, furosemide-resistant, urine output

DOI: https://doi.org/10.21203/rs.3.rs-52612/v1

License: This work is licensed under a Creative Commons Attribution 4.0 International License.
Read Full License
Abstract

**Background** Tolvaptan (TLV), a vasopressin type 2 receptor antagonist, is an effective drug for heart failure without worsening renal function. However, the effect of TLV on nephrotic syndrome remains unknown. This study aims to assess the association between response to TLV and clinical parameters including pathological evaluation in nephrotic patients with diuretics-resistance.

**Methods** For prospectively enrolled patients, TLV was added for 14 days after renal biopsy performed. We evaluated the effect of TLV on urine output (UO) and body weight (BW) and the correlation of UO change with BW, urine and blood measurements and pathological evaluation. Pathological evaluation included glomerular sclerosis, tubulointerstitial injury, interstitial fibrosis and the degree of aquaporin 2 (AQP2) positivity in collecting ducts.

**Results** Ten nephrotic patients were enrolled. Two patients already received 140 and 160mg furosemide and others 40mg furosemide before TLV. After TLV administration, no patients showed worsening renal function or hypernatremia (>145 mEq/L) and two patients without any improvement of symptoms discontinued the trial. TLV significantly increased UO at day 1 and decreased BW overall. UO increase at day 1 was significantly correlated with BW decrease at the last follow-up. UO increase at day 1 was correlated only with AQP2 positivity in collecting ducts on biopsied kidney ($r^2=0.59$, $p=0.01$) while other urine and blood measurements were not.

**Conclusions** TLV was effective on nephrotic patients. UO increase by TLV was correlated with AQP2 positivity in the collecting ducts while biochemistry in urine and blood was not.

Background

Tolvaptan (TLV) is an antagonist of vasopressin type 2 receptor and promotes water diuresis. The first study reports that TLV is effective for the syndrome of inappropriate secretion of antidiuretic hormone (SIADH) to correct hyponatremia\(^1\). And now TLV plays an important role in treating patients with acute and chronic heart failure refractory to other diuretics\(^2\). Responders to TLV experienced not only a better clinical course but better prognosis in both short- and long-term observation \(^3\). Moreover, TLV has no adverse effect on neurohormonal activation or renal activation while other diuretics can exaggerate neurohormonal imbalance and cause vasoconstriction with the reduction of renal perfusion. The previous clinical trial showed TLV helped weight loss and better relief of dyspnea without worsening renal function in heart failure patients\(^4\).

Nephrotic syndrome is also a state of fluid overload with decreased urine volume and often accompanied with renal dysfunction. Although the pathophysiology of sodium and water retention in nephrotic syndrome has not been precisely clarified, activation of the renin-angiotensin aldosterone system and sympathetic nervous system is referred as a part of causes. Underfilled circulation to kidneys activates these neurohormonal systems and may worsen renal function\(^5\). Vasopressin type 2 receptor antagonists,
which are not expected to cause neurohormonal imbalance, will be an ideal agent to treat hypervolemia in nephrotic syndrome without worsening renal function\textsuperscript{6}.

Although some case reports showed TLV was effective in patients with nephrotic syndrome\textsuperscript{7,8}, it has not been fully elucidated which nephrotic patients are responsive to TLV. Also, nephrotic patients sometimes have renal impairment\textsuperscript{9,10}, which is one of the major risk factors for resistance to TLV\textsuperscript{11}. Thus, it is required to evaluate whether nephrotic syndrome is responsive to TLV and whether the response to TLV can be predicted by urine, blood or pathological test.

This study aims to evaluate 1) responsiveness for TLV treatment and 2) associating factors including serum and urinary biochemical parameters, urinary aquaporin (AQP) 2, serum TLV concentration, renal pathological findings, and renal AQP2 expression for TLV effectiveness, in patients with diuretics-resistant nephrotic syndrome.

**Methods**

**Patient enrollment**

The inclusion criteria were (a) nephrotic syndrome and (b) fluid overload resistant to diuretics. Nephrotic syndrome was defined as > 3.5 g/day proteinuria and hypoalbuminemia (< 3.0 g/dL). Diuretic resistance was defined that volume overload remained even when furosemide dose was 40 mg or more. The exclusion criteria were patients with allergy to vaptans, anuria (< 200 mL/day), difficulty to free water intake, hypernatremia (> 147 mEq/L), or pregnancy.

**Study Protocol**

This was a prospective exploratory study conducted from January through December in 2014. The study design is shown as Supplemental Figure S1. Evaluation of the degree of edema, chest X-ray, echocardiogram, and renal biopsy was performed at the screening phase before TLV administration. Then TLV 7.5 mg per day was added on enrolled patients for 14 days. During the trial, other diuretics than TLV were continued with unchanged doses. If urine output did not increase or symptoms were not improved for two days after 7.5 mg of TLV administration, the dose of TLV could be increased to 15 mg as needed. During TLV administration, water intake was not restricted to prevent volume depletion.

Body weight, daily urine output, blood pressure and pulse rate were checked every day. Serum and urine osmolality, serum sodium and creatinine were measured before TLV administration, and at 4hr, 8hr, day2, 3, 5, 8, and 15 after TLV medication.

Patients were followed up until day 15 if TLV was effective and safe. Follow up was finished at the time when symptoms were not improved or exaggerated and continuing trial was considered as a risk during the trial.
This study protocol was approved by Tokushukai Group Institutional Review Board (TGE00343-024) and adhered to the Declaration of Helsinki and to CONSORT guidelines. Informed consents were obtained before the study registration by written form. This study was also registered in UMIN-CTR (UMIN000011763).

Measurement of urine AQP2, serum TLV concentration and anti-diuretic hormone (ADH).

Urine AQP2 before TLV administration was determined using sandwich enzyme-linked immunosorbent assay (human AQP2 ELISA kit, LSI Medience) as described previously. Serum TLV concentration was evaluated at 4 hour after TLV administration on day 1, and determined using a validated high-performance liquid chromatography-tandem mass spectrometry method at Toray Research Center, Inc. Details have been described previously. Plasma ADH before TLV administration was determined using commercially available enzyme-linked immunosorbent assay (ELISA) kits.

Pathological evaluation

To evaluate the collagen deposition, 2 µm sections of paraffin-embedded tissue were subjected to Masson Trichrome staining (MTS) by routine procedures. Stained sections were examined by Olympus BX50 epifluorescence microscope equipped with a digital camera DP73 (Tokyo, Japan). To estimate fibrotic area, computer-aided morphometric analysis on MTS sections was performed as described previously. Briefly, a grid containing 117 (13 × 9) sampling points was superimposed on images of a cortical high-power field (x400). The number of grid points overlying the MTS-positive area was counted and expressed as a percentage of all sampling points. For each kidney specimen, 10 randomly selected non-overlapping fields were analyzed.

To evaluate glomerular sclerosis, 2 µm sections of paraffin-embedded tissue were subjected to hematoxylin-eosin staining by routine procedures. All glomeruli in tissue slice were evaluated at × 400 using a semiquantitative scoring method as follows: grade 0, no obvious sclerosis (normal); grade 1, sclerotic area 25% (minimal sclerosis); grade 2, sclerotic area 25–50% (moderate sclerosis); grade 3, sclerotic area 50–75% (moderate-severe sclerosis); and grade 4, sclerotic area 75–100% (severe sclerosis). The glomerulosclerotic index (GSI) was calculated using the weighted average of > 10 glomeruli.

Tubulointerstitial injury in the cortex was analyzed histomorphometrically by counting the number of tubules that demonstrated vacuolar degeneration, chromatin condensation of tubular nuclei, tubular dilatation and thickened and/or wrinkled tubular basement membranes divided by the number of total tubules per field (× 200) in 10 randomly selected cortical fields per cross Sect.

To compare the histological features in participants, three patients with minor glomerular abnormality and normal renal function were evaluated as controls (N = 3). The pathological evaluation was performed by well-trained nephrologists.

Immunohistochemical staining and evaluation of AQP2 immunostaining
Two micrometer of formalin-fixed specimen were used for AQP2 immunostaining. After deparaffinization, endogenous peroxidase activity was blocked by 0.3% H$_2$O$_2$ in methanol for 20 minutes at room temperature. Then sections were incubated with Rabbit anti-human AQP2 (C-17) antibody (1:100 dilution; Santa Cruz Biotechnology, Santa Cruz, CA) for primary antibody for an hour at room temperature. Bound antibodies were detected with peroxidase-conjugated goat anti-rabbit antibody (Histofine Simple Stain MAX PO; Nichirei Biosciences, Tokyo, Japan) using diaminobenzidine-tetrahydrochloride (DAB) (Simple Stain DAB solution; Nichirei Biosciences, Tokyo, Japan) as the substrate for 30 minutes at room temperature. The sections were counterstained with hematoxylin. The normal part of the whole kidney with clear cell carcinoma was used for normal control.

We defined the proportion of AQP2 staining as the proportion of the number of stained cells divided by the number of all cells in a sectional collecting duct. The example in Supplemental Figure S2 shows five AQP2-positive cells (red arrows) of twelve cells so that the proportion of AQP2 staining is 0.42. AQP2 positivity was evaluated in all collecting ducts in each kidney specimen in each patient.

**Statistical analysis**

Data were presented as median (interquartile). Wilcoxon ranked test was used for rejecting the null hypothesis that the change of UO and BW was not significant. Wilcoxon ranked test was used when comparing between time-serial data on osmolality and electrolytes in urine and serum because all data were not normally distributed. The existence of correlation between two continuous variables was determined using Spearman correlation. We did statistical analyses by JMP Pro 11 for Windows (SAS Institute Japan, Tokyo). A significant difference was defined as p-value < 0.05.

**Results**

**Baseline characteristics**

Ten patients with nephrotic syndrome were enrolled and Table 1 describes their baseline characteristics. Two patients already received 140 and 160 mg furosemide and others 40 mg furosemide before TLV. Diabetic nephropathy was the majority in the causes of nephrotic syndrome and 9 patients had renal impairment. No one had very low cardiac output (EF < 30%). The median of urine osmolality was lower than the predictive value for responsiveness to TLV in the previous report.$^{18}$
Table 1
Baseline characteristics

| Age (y)      | 66 (49–70) |
|--------------|------------|
| M/F          | 7/3        |
| Height (cm)  | 166.5 (151.8–174.3) |
| Weight (kg)  | 79.4 (70.8–90.2) |
| Causes       |            |
| DN           | 8 (80%)    |
| MCNS         | 2 (20%)    |
| Hypertension | 6 (60%)    |
| NYHA classification |        |
| II           | 3 (30%)    |
| III          | 4 (40%)    |
| IV           | 3 (30%)    |
| Nohria classification |    |
| B            | 9 (90%)    |
| C            | 1 (10%)    |
| Systolic blood pressure (mmHg) | 133 (123–171) |
| Heart rate (/min) | 68 (64–87) |
| Ejection Fraction (%) | 60 (41–67) |
| Diameter of IVC at exhalation (mm) | 4.7 (4.1–11.9) |
| Diameter of IVC at inhalation (mm) | 18 (15.2–21.7) |
| Total protein (g/dL) | 5 (4.1–5.5) |
| Albumin (g/dL)     | 2.0 (1.8–2.2) |
| UN (mg/dL)        | 21.2 (18.9–32.2) |
| Creatinine (mg/dL) | 1.79 (1.32–2.43) |
| eGFR (mL/min/1.73 m^2) | 27.5 (21.2–43.1) |
| Sodium (mEq/L)    | 140 (138–142) |

ADH, anti-diuretic hormone; AQP2, aquaporin 2; BNP, brain natriuretic peptide; DN, diabetic nephropathy; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; IVC, inferior vena cava; MCNS, minimal change nephrotic syndrome; TLV, tolvaptan; UN, urea nitrogen
| Age (y) | 66 (49–70) |
|---------|------------|
| Potassium (mEq/L) | 3.9 (3.4–4.2) |
| Chloride (mEq/L) | 103 (102–108) |
| Total Cholesterol (mg/dL) | 181 (153–232) |
| Triglyceride (mg/dL) | 90 (74–131) |
| LDL-C (mg/dL) | 119 (75–185) |
| HDL-C (mg/dL) | 43.7 (39.3–49.0) |
| Hemoglobin A1c (%) | 6.3 (5.8–8.3) |
| Serum osmolality (mOsm/kg) | 289 (285–293) |
| BNP (pg/mL) | 321 (74–663) |
| ADH (pg/mL) | 2.1 (1.6–4.0) |
| Renin (ng/mL/hr) | 0.6 (0.4–2.0) |
| Aldosterone (pg/mL) | 43.8 (33.1–63.6) |
| Urine osmolality (mOsm/kg) | 321 (258–337) |
| Urinary protein (g/day) | 6.86 (4.16–9.46) |
| Urine UN (mg/dL) | 327 (139–507) |
| Urine creatinine (mg/dL) | 57.4 (35–117) |
| Urine sodium (mEq/L) | 68.5 (48.5–94.5) |
| Urine potassium (mEq/L) | 15.6 (11.8–28.1) |
| Urine chloride (mEq/L) | 56.5 (43–109) |
| Urine AQP2 (ng/mL) | 0.83 (0.57–1.31) |
| TLV concentration (ng/mL) | 95.2 (64.9–134.3) |

ADH, anti-diuretic hormone; AQP2, aquaporin 2; BNP, brain natriuretic peptide; DN, diabetic nephropathy; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; IVC, inferior vena cava; MCNS, minimal change nephrotic syndrome; TLV, tolvaptan; UN, urea nitrogen

Five patients finished follow-up before day 15 because of no improvement of symptoms (N = 2) or discharge in alive (N = 3). The remaining five patients were followed up until day 15.

The pathological evaluation was exhibited in Supplemental Figure S3. When compared with patients with minor glomerular abnormality and normal renal function, nephrotic patients had more glomerular
sclerosis and tubulointerstitial injury, while interstitial fibrosis was not significantly different between 2 groups.

**Osmolality and electrolytes in urine and serum after TLV administration**

The time-dependent course of osmolality and electrolytes in spot urine, and serum are depicted in Supplemental Figure S4. Spot urine osmolality and electrolytes significantly decreased four and eight hours after TLV administration and returned to baseline at day 2 or after. On the other hand, except the increase of serum osmolality at day 2 and serum chloride at day 2–3, serum osmolality and electrolytes were unchanged during TLV administration. All patients did not suffer from any electrolyte disorders including hypernatremia (> 145 mEq/L) and did not have worsening renal function with repetitive TLV administration.

**Effect and safety of TLV in patients with nephrotic syndrome**

Urine output at day 1 exhibited a significant increase from baseline and urine output after day 1 was not significantly different from baseline. Body weight was significantly reduced at the last follow-up after TLV administration (Fig. 1).

When the correlation with urine output and weight change at last follow-up was evaluated, the change of urine output at day 1 was significantly correlated with weight change at last follow-up ($R^2 = 0.52, p = 0.02$).

**No association with urine output increase by TLV and various measurements in urine and blood.**

Although some measurements in urine and blood changed after TLV administration (Supplemental Figure S4), the change of UO at day 1 was not correlated with osmolality and electrolytes in urine and serum before TLV administration (Table 2). Also, the change of urine output on day 1 did not correlate with urine AQP2 before administration. As same as urine AQP2, the concentration of TLV and plasma ADH were not related to the change of urine output. (Table 3)

**Table 2:**

The correlation of urine output change at day 1 with urine and serological measurements.

None of them were associated with urine output.
|               | R²  | p-value |
|---------------|-----|---------|
| Spot urine    |     |         |
| Osmolality    | 0.03| 0.62    |
| Sodium        | 0.04| 0.58    |
| Potassium     | 0.01| 0.74    |
| Chloride      | 0.07| 0.48    |
| Protein       | 0.004| 0.86   |
| Creatinine    | 0.002| 0.90   |
| UN            | 0.01| 0.75    |
| Serum         |     |         |
| Osmolality    | 0.05| 0.52    |
| Creatinine    | 0.07| 0.45    |
| UN            | 0.04| 0.56    |
| Urine AQP2    | 0.07| 0.45    |
| Plasma ADH    | 0.05| 0.58    |
| Serum TLV     | 0.03| 0.65    |

Abbreviations: AQP2, aquaporin 2; ADH, antidiuretic hormone; TLV, tolvaptan; UN, urea nitrogen.
Table 3
The correlation of urine output change on day 1 with pathological evaluation.

|                         | R²  | p-value |
|-------------------------|-----|---------|
| **Spot urine**          |     |         |
| Osmolality              | 0.03| 0.62    |
| Sodium                  | 0.04| 0.58    |
| Potassium               | 0.01| 0.74    |
| Chloride                | 0.07| 0.48    |
| Protein                 | 0.004| 0.86   |
| Creatinine              | 0.002| 0.90   |
| UN                      | 0.01| 0.75    |
| **Serum**               |     |         |
| Osmolality              | 0.05| 0.52    |
| Creatinine              | 0.07| 0.45    |
| UN                      | 0.04| 0.56    |
| **Urine AQP2**          |     |         |
|                         | 0.07| 0.45    |
| **Plasma ADH**          |     |         |
|                         | 0.05| 0.58    |
| **Serum TLV**           |     |         |
|                         | 0.03| 0.65    |

| **Pathological parameters** | R²  | p-value |
|----------------------------|-----|---------|
| Fibrosis                   | 0.01| 0.79    |
| GSI                        | 0.11| 0.36    |
| TI                         | 0.08| 0.42    |
| AQP2                       | 0.59| 0.01    |

Abbreviations: GSI, glomerular sclerosis index; TI, tubulointerstitial injury

Pathological evaluation revealed the degree of AQP2 staining was related to urine output

Then urine output change was evaluated from the pathological point. The proportion of AQP2 staining was strongly correlated with urine output change at day 1 while the degree of fibrosis, glomerular
sclerosis and tubulointerstitial injury were not significantly correlated with urine output change at day 1 (Table 3).

Discussion

Nephrotic syndrome is common kidney disease. Some nephrotic patients have refractory edema resistant to near-maximum doses of diuretics \(^{19,20}\). Also, volume correction and the use of diuretics may deteriorate renal function \(^{21,22}\). Optimal treatment for nephrotic edema without worsening renal function is an important issue. An antagonist to V2 receptor, TLV, blocks water reabsorption via aquaporin 2 in cortical collecting ducts without activating the renin-angiotensin-aldosterone axis and the sympathetic nervous system \(^{6}\). TLV is expected as a novel drug for nephrotic edema. However, to date, it remains to be clarified who is responsive to TLV though some researchers reported the effect of TLV on nephrotic edema. Then our study challenged to elucidate the association of responsiveness to TLV with pathological evaluation and serological or urinary markers. And the novel findings are as below. First, urine output change at day 1 was correlated with the degree of weight loss at the final. Second, the proportion of AQP2 staining was correlated with the increase of urine output by TLV while urine and blood measurements including uAQP2 and TLV were not correlated. And finally, TLV could be used safely for some nephrotic patients without adverse effects in the short term.

Previous reports showed that responders to TLV in heart failure patients had a significant increase in urine volume soon after administration and improved clinical course with significant weight loss \(^{23}\). As similar to the previous studies, our study demonstrated that weight loss was also significantly related to the increase of urine volume at day 1 in nephrotic syndrome. This indicated that urine volume soon after TLV administration was enough to evaluate whether it was responsive to TLV and the clinical course was improved in nephrotic syndrome patients.

A transient increase in urine output on day 1 was not reflected in a concomitant weight loss on day 2. This undesirable result is attributed to arbitrary water intake. In general, fluid restriction is needed for volume control irrespective of the use of diuretics. However, at the time when this study was conducted, Pharmaceuticals and Medical Devices Agency in Japan did not recommend fluid restriction to avoid volume depletion. Moreover, we could not predict the urine output increase so that we could not manage volume control appropriately. But the result in this study revealed the effect of TLV and we would manage the proper fluid restriction.

Urine AQP2, urine osmolality change and serum TLV concentration can be predictors for TLV efficacy in heart failure \(^{18,24,25}\). However, these measurements did not correlate with urine output change and weight loss in our study despite detected urine AQP2, the reduction of urine osmolality and elevated TLV concentration. Moreover, serum ADH was not correlated with the effect of TLV. There were no precise explanations, but some reasons could be speculated. First, evidence was not enough about the association with urine AQP2 and pathological AQP2 staining in nephrotic syndrome though AQP2 expression in kidney tissues and net urine AQP2 were increased in a previous report \(^{26}\).
nephrotic patients sometimes decreases and urine AQP2 concentration needs to be adjusted when it is interpreted. However, AQP2 is located and excreted in principal cells of collecting ducts. Urine creatinine or other filtration makers were not enough as calibrations because they do not reflect the dynamics of collecting ducts precisely. Thus, urine AQP2 concentration did not correlate with AQP2 staining and urine output change in nephrotic patients. Second, the majority in our study had renal impairment, unlike previous reports. Patients with decreased eGFR disable to dilute or concentrate urine despite elevated vasopressin concentration, which indicates collecting ducts in the diseased kidney are reluctant to respond to vasopressin and V2 receptor antagonists. Serum ADH is slightly higher in CKD patients, which indicates that the response to ADH would be sluggish. Although the mechanism of urine dilution and concentration is not clearly understood, it is considered that urine osmolality, serum ADH or TLV concentration were not enough to predict the aquauresis by TLV.

Although the finding in this study indicates that it requires a renal biopsy to predict urine output change by TLV in nephrotic patients, renal biopsy is impractical only for the purpose. Biopsy has several risks such as flank pain, infection and bleeding. A few days are necessary for the result of the biopsy. Thus, the finding in this study may makes little clinical sense and a novel, easier manner will be expected for predicting the responsiveness. However, although it may not give a suggestion to our clinical practice immediately, we believe that this finding in this study is academically important. Our findings are not totally consistent with previous studies because we found that the effect of tolvaptan retained for patients with kidney dysfunction, but was correlated with AQP2 in biopsied kidney, not urine and blood parameters like the previous studies. Thus, we consider this finding should be described in this article to further understand the physiology of diuresis under kidney impairment.

The limitation of this study is a small exploratory study in a single center for the short term. The population in this study was limited to nephrotic patients with diabetic nephropathy and CKD stage 3–4. The pathophysiology of diabetic nephropathy and nephrotic patients may be different as indicated in the previous report. It is postulated that nephrotic syndrome results from permeability factors affecting podocyte function such as cardiotrophin-like cytokine 1, which is not regarded as a cause of diabetic nephrophaty. Therefore, this study cannot tell that tolvaptan is effective for idiopathic nephrotic syndrome and further studied are required. Second, the number of enrolled patients could not be reached to the target size (N = 20) during the trial. More detail evaluation for the larger population and other types of nephrotic syndrome is needed. The long term effect of TLV should be evaluated in further study. Third, this study was an exploratory study, not a randomized trial with controls of conventional therapy. Further randomized comparative trials are needed to validate the efficacy of tolvaptan. Fourth, low dose TLV in this study may be a potential limitation. According to the report on the pharmacokinetics of TLV, even higher dose TLV have less effect on urine excretion in advanced kidney disease. Therefore, higher dose might have increased urine output in some patients without any improvement of symptom in this study.

**Conclusion**
Our exploratory prospective study provided that TLV increased urine output in nephrotic patients and the increase of urine output by TLV was only correlated with AQP2 positivity in kidney tissue. Urinary and serological measurements were not correlated with the effect of TLV, and no clinical parameters except kidney biopsy specimen may predict the responsiveness for TLV in patients with nephrotic syndrome.

Declarations

**Ethics approval and consent to participate:**

This study protocol was approved by Tokushukai Group Institutional Review Board (TGE00343-024) and adhered to the Declaration of Helsinki. Informed consents were obtained before the study registration by written form. Trial registration: UMIN-CTR, UMIN000011763. Registered 20 August 2013, https://upload.umin.ac.jp/cgi-open-bin/ctr/ctr.cgi?function=brows&action=brows&recptno=R000013754&type=summary&language=J

**Availability of data and materials:** All data generated or analysed during this study are included in this published article [and its supplementary information files].

**Competing interests**

Dr. Koichiro Kinugawa received honorarium from Otsuka Pharmaceutical co. Other authors declared no competing interests

**Funding:** None

**Author's contribution**

RM and TO conceived and designed the study, analyzed the data, and drafted the manuscript. YM, KI, KM, and MO conducted the data collection. SH, TI, KK and SK provided additional guidance for the analysis. All authors revised the manuscript critically for important intellectual content and gave final approval of the manuscript.

**Acknowledgment:** None.

**Consent for publication:** Not Applicable

**References**

1. Saito T, Ishikawa S, Abe K, et al. Acute aquaresis by the nonpeptide arginine vasopressin (AVP) antagonist OPC-31260 improves hyponatremia in patients with syndrome of inappropriate secretion of antidiuretic hormone (SIADH). J Clin Endocrinol Metab 1997;82:1054-1057

2. Imamura T. Aquaporin-2-guided tolvaptan therapy in patients with congestive heart failure accompanied by chronic kidney disease. *International heart journal*. 2014;55:482-483.
3. Imamura T, Kinugawa K, Minatsuki S, et al. Tolvaptan can improve clinical course in responders. *International heart journal*. 2013;54:377-381.

4. Matsue Y, Suzuki M, Torii S, et al. Clinical Effectiveness of Tolvaptan in Patients With Acute Heart Failure and Renal Dysfunction. *Journal of cardiac failure*. 2016;22:423-432.

5. Schrier RW, Fassett RG. A critique of the overfill hypothesis of sodium and water retention in the nephrotic syndrome. *Kidney Int*. 1998;53:1111-1117.

6. Costello-Boerrigter LC, Smith WB, Boerrigter G, et al. Vasopressin-2-receptor antagonism augments water excretion without changes in renal hemodynamics or sodium and potassium excretion in human heart failure. *American journal of physiology. Renal physiology*. 2006;290:F273-278.

7. Shimizu M, Ishikawa S, Yachi Y, et al. Tolvaptan therapy for massive edema in a patient with nephrotic syndrome. *Pediatric nephrology (Berlin, Germany)*. 2014;29:915-917.

8. Tanaka A, Nakamura T, Sato E, Ueda Y, Node K. Different Effects of Tolvaptan in Patients with Idiopathic Membranous Nephropathy with Nephrotic Syndrome. *Internal medicine (Tokyo, Japan)*. 2017;56:191-196.

9. Maas RJ, Deegens JK, Beukhof JR, et al. The Clinical Course of Minimal Change Nephrotic Syndrome With Onset in Adulthood or Late Adolescence: A Case Series. *American journal of kidney diseases : the official journal of the National Kidney Foundation*. 2017.

10. Nielsen SE, Reinhard H, Zdunek D, et al. Tubular markers are associated with decline in kidney function in proteinuric type 2 diabetic patients. *Diabetes research and clinical practice*. 2012;97:71-76.

11. Toda H, Nakamura K, Nakahama M, et al. Clinical characteristics of responders to treatment with tolvaptan in patients with acute decompensated heart failure: Importance of preserved kidney size. *Journal of cardiology*. 2016;67:177-183.

12. Umenishi F, Summer SN, Cadnapaphornchai M, Schrier RW. Comparison of three methods to quantify urinary aquaporin-2 protein. *Kidney Int*. 2002;62:2288-2293.

13. Sasaki S, Ohmoto Y, Mori T, Iwata F, Muraguchi M. Daily variance of urinary excretion of AQP2 determined by sandwich ELISA method. *Clinical and experimental nephrology*. 2012;16:406-410.

14. Kim SR, Hasunuma T, Sato O, Okada T, Kondo M, Azuma J. Pharmacokinetics, pharmacodynamics and safety of tolvaptan, a novel, oral, selective nonpeptide AVP V2-receptor antagonist: results of single- and multiple-dose studies in healthy Japanese male volunteers. *Cardiovascular drugs and therapy*. 2011;25 Suppl 1:S5-17.

15. Hao S, He W, Li Y, et al. Targeted inhibition of beta-catenin/CBP signaling ameliorates renal interstitial fibrosis. *Journal of the American Society of Nephrology : JASN*. 2011;22:1642-1653.

16. Garman JH, Mulroney S, Manigrasso M, Flynn E, Maric C. Omega-3 fatty acid rich diet prevents diabetic renal disease. *American journal of physiology. Renal physiology*. 2009;296:F306-316.

17. Taneda S, Honda K, Tomidokoro K, Uto K, Nitta K, Oda H. Eicosapentaenoic acid restores diabetic tubular injury through regulating oxidative stress and mitochondrial apoptosis. *American journal of physiology. Renal physiology*. 2010;299:F1451-1461.
18. Imamura T, Kinugawa K, Shiga T, et al. Novel criteria of urine osmolality effectively predict response to tolvaptan in decompensated heart failure patients–association between non-responders and chronic kidney disease. Circulation journal : official journal of the Japanese Circulation Society. 2013;77:397-404.

19. Vasudevan A, Mantan M, Bagga A. Management of edema in nephrotic syndrome. Indian pediatrics. 2004;41:787-795.

20. Hoorn EJ, Ellison DH. Diuretic Resistance. American journal of kidney diseases : the official journal of the National Kidney Foundation. 2017;69:136-142.

21. Felker GM, Lee KL, Bull DA, et al. Diuretic strategies in patients with acute decompensated heart failure. N Engl J Med. 2011;364:797-805.

22. Damman K, Testani JM. The kidney in heart failure: an update. European heart journal. 2015;36:1437-1444.

23. Tamaki S, Sato Y, Yamada T, et al. Tolvaptan Reduces the Risk of Worsening Renal Function in Patients With Acute Decompensated Heart Failure and Preserved Left Ventricular Ejection Fraction-Prospective Randomized Controlled Study. Circulation journal : official journal of the Japanese Circulation Society. 2017.

24. Imamura T, Kinugawa K, Fujino T, et al. Increased urine aquaporin-2 relative to plasma arginine vasopressin is a novel marker of response to tolvaptan in patients with decompensated heart failure. Circulation journal : official journal of the Japanese Circulation Society. 2014;78:2240-2249.

25. Kato M, Tohyama K, Ohya T, Hiro T, Hirayama A. Association between plasma concentration of tolvaptan and urine volume in acute decompensated heart failure patients with fluid overload. Cardiology journal. 2016.

26. Wang Y, Bu J, Zhang Q, Chen K, Zhang J, Bao X. Expression pattern of aquaporins in patients with primary nephrotic syndrome with edema. Molecular medicine reports. 2015;12:5625-5632.

27. Roussel R, Fezeu L, Marre M, et al. Comparison between copeptin and vasopressin in a population from the community and in people with chronic kidney disease. The Journal of clinical endocrinology and metabolism. 2014;99:4656-4663.

28. Gallon L, Leventhal J, Skaro A, Kanwar Y, Alvarado A: Resolution of recurrent focal segmental glomerulosclerosis after retransplantation. N Engl J Med 2012;366:1648–1649

29. Wada, T. & Nangaku, M. A circulating permeability factor in focal segmental glomerulosclerosis: the hunt continues. Clin. Kidney J. 2015; 8, 708–15

30. Davin JC: The glomerular permeability factors in idiopathic nephrotic syndrome. Pediatr Nephrol 2016; 31: 207–215

31. S.E. Shoaf, P. Bricmont, S. Mallikaarjun. Pharmacokinetics and pharmacodynamics of oral tolvaptan in patients with varying degrees of renal function. Kidney Int, 85 (2014), pp. 953-961

Figures
Figure 1

The change of urine output and body weight in a day after TLV administration. This figure shows the time-dependent course of the change of (a) urine output (mL/day) and (b) body weight (kg) compared to those before TLV administration. (a) The significant increase of urine output was observed only at day 1. (b) The significant decrease in body weight was observed at day 4, 5 and last follow-up. Box plot shows median and interquartile range. * p<0.05.

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- additionalfileCONSORTChecklist.docx
- Supplemental.docx